Show simple item record

Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time

dc.contributor.authorJalal Eldin, Abdel W
dc.contributor.authorTombayoglu, Dilara
dc.contributor.authorButz, Laura
dc.contributor.authorAffinati, Alison
dc.contributor.authorMeral, Rasimcan
dc.contributor.authorOntan, Mehmet S
dc.contributor.authorWalkovich, Kelly
dc.contributor.authorWesterhoff, Maria
dc.contributor.authorInnis, Jeffrey W
dc.contributor.authorParikh, Neehar D
dc.contributor.authorOral, Elif A
dc.date.accessioned2019-11-26T13:55:04Z
dc.date.available2019-11-26T13:55:04Z
dc.date.issued2019-07-09
dc.identifier.citationClinical Diabetes and Endocrinology. 2019 Jul 09;5(1):9
dc.identifier.urihttps://doi.org/10.1186/s40842-019-0082-y
dc.identifier.urihttps://hdl.handle.net/2027.42/152255
dc.description.abstractAbsract Background Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) is a rare syndrome with unknown etiology. Metabolic abnormalities are not known to be part of the syndrome. We present one of the oldest cases reported in the literature, who developed severe metabolic abnormalities and hepatic disease suggesting that these features may be part of the syndrome. Case presentation A 27-year-old woman, diagnosed with ROHHAD syndrome at age 15, who previously developed diabetes insipidus, growth hormone deficiency, hyperprolactinemia, and hypothyroidism in her first decade of life. This was followed by insulin resistance, NAFLD, liver fibrosis, and splenomegaly before age 14 years. Her regimen included a short course of growth hormone, and cyclic estrogen and progesterone. Her metabolic deterioration continued despite treatment with metformin. Interestingly, she had a favorable response to liraglutide therapy despite having a centrally mediated cause for her obesity. At age 26, a 1.6 cm lesion was found incidentally in her liver. Liver biopsy showed hepatocellular carcinoma which was successfully treated with radiofrequency ablation. Conclusion Metabolic abnormalities, Insulin resistance and fatty liver disease are potentially part of the ROHHAD syndrome that may develop over time. GLP1 agonists were reasonably effective to treat insulin resistance and hyperphagia. Patients with ROHHAD may benefit from close follow up in regards to liver disease.
dc.titleNatural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time
dc.typeArticleen_US
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/152255/1/40842_2019_Article_82.pdf
dc.language.rfc3066en
dc.rights.holderThe Author(s).
dc.date.updated2019-11-26T13:55:05Z
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.